Overview of US Patent 11,617,751
US Patent 11,617,751 was granted to Moderna, Inc. on April 4, 2023. It covers a novel mRNA-based vaccine technology. The patent primarily claims improvements in lipid nanoparticle delivery systems and specific modifications to the mRNA sequence for enhanced stability and efficacy.
Scope and Key Claims
Main Focus:
The patent claims encompass a platform for vaccine delivery that employs lipid nanoparticles (LNPs) containing specific ionizable lipids, along with modified mRNA constructs designed to increase mRNA stability and translational efficiency. It aims to improve the immune response and reduce side effects compared to earlier mRNA vaccines.
Core Claims:
-
LNP Composition:
Claims align on specific lipid formulations characterized by a particular ionizable lipid, helper lipids, cholesterol, and PEG-lipid content. The composition is designed to enhance stability and reduce toxicity.
-
mRNA Modifications:
The patent claims include mRNA sequences with nucleoside modifications (e.g., pseudouridine, 5-methylcytidine) that improve translational efficiency and decrease innate immune activation.
-
Delivery Method:
The patent covers methods of administering the vaccine, including dosing regimens and formulations for intramuscular injection.
-
Manufacturing Processes:
Claims extend to processes for synthesizing and encapsulating the mRNA in lipid nanoparticles, emphasizing scalable methods compatible with commercial production.
Claims Hierarchy:
- Independent claims focus on the composition and methods.
- Dependent claims specify narrow features, such as specific lipid ratios, mRNA modifications, or formulation conditions.
Patent Landscape and Comparative Analysis
Proprietary Scope:
The patent holds a broad claim set on lipid nanoparticle formulations and mRNA modifications, impacting key development areas for mRNA vaccines and therapeutics.
Related Patents:
Other relevant patents include:
- Cationic lipids and ionizable lipids: Patents from BioNTech/Pfizer (e.g., US Patent 10,927,492) with similar lipid compositions.
- mRNA modifications: Patents covering nucleoside modifications, such as US Patent 9,849,301 assigned to Moderna.
- Delivery methods: Patents on injection techniques and nanoparticle formulations by Novartis and CureVac.
Patent Family and Continuations:
Moderna maintains a robust patent family covering various aspects of mRNA delivery and modification to prevent third-party encroachment. Several continuation applications refine claims on lipid composition and manufacturing processes.
Legal Status:
- The patent is granted and enforceable until at least 2043, with multiple continuations and provisional applications pending.
- No current litigations filed explicitly against this patent; however, opposition or challenge could arise from competitors.
Filing Trends in mRNA Vaccine Patents
- Moderna: Filed over 150 patent applications related to mRNA technology since 2015. Focuses on lipid nanoparticle formulations, mRNA stability, and manufacturing.
- BioNTech/Pfizer: Filed multiple patents covering lipid carriers, nucleoside modifications, and delivery systems since 2016.
- CureVac: Focuses on unmodified mRNA and alternative delivery methods.
Patent Filings by Year:
Between 2018 and 2022, US patent filings surged, indicating strategic protection efforts as mRNA vaccine technology matured.
Innovation and Competitive Positioning
- Moderna's patent claims extend beyond vaccine use to encompass broader mRNA therapeutic applications.
- The claims’ broad scope on lipid formulations strengthen Moderna's position in the mRNA space, covering current and future products.
- Competing players' patents tend to focus on specific lipid structures or modifications, creating room for design-around strategies.
Risks & Limitations
- Patent Thicket: Overlapping claims across key innovators may complicate licensing or freedom-to-operate assessments.
- Evolving Science: Rapid advances in lipid chemistry and nucleotide modifications could render some claims narrower over time.
- Legal Challenges: Potential for patent validity disputes, particularly concerning claim inventiveness and prior art.
Key Takeaways
- US Patent 11,617,751 claims a comprehensive platform for mRNA vaccine delivery, focusing on specific lipid formulations and mRNA modifications.
- Its broad scope covers multiple aspects of mRNA vaccine technology, reinforcing Moderna's intellectual property position.
- The patent landscape features a mix of overlapping claims from companies like BioNTech, CureVac, and Moderna, with ongoing patent prosecution and continuation filings.
- Patent risks include legal challenges, overlapping claim sets, and rapid technological evolution.
- For companies aiming to enter or expand in mRNA therapeutics, understanding this patent’s scope is critical for strategic R&D, licensing, or design-around efforts.
FAQs
Q1: How does US Patent 11,617,751 compare to earlier Moderna patents?
It expands on prior filings by covering specific lipid nanoparticle compositions and nucleoside modification strategies not previously claimed, increasing the breadth of Moderna’s patent estate in mRNA technology.
Q2: Can this patent block other companies from developing similar mRNA vaccines?
It provides exclusive rights specific to its claims; however, alternative formulations or different delivery systems not covered by the claims might avoid infringement.
Q3: Are there similar patents from competitors that could impact Moderna’s patent rights?
Yes, patents from BioNTech and CureVac focus on related lipid formulations and nucleoside modifications, creating potential areas for licensing negotiations or design-around strategies.
Q4: What is the duration of patent protection for US Patent 11,617,751?
It is enforceable until 2043, assuming maintenance fees are paid and no invalidation challenges are successful.
Q5: How do patent filings in this space impact future mRNA development?
They create a dense patent landscape; innovators must carefully navigate existing rights, pursue licensing, or develop alternative technologies to avoid infringement.
References
[1] US Patent 11,617,751.
[2] Moderna's patent portfolio overview (2023).
[3] BioNTech’s related patent applications (public domain).
[4] Patent filing trends in mRNA technology (2015–2022).
